RxDoctor Payments Data

Priyanka Sood, MD

Ophthalmology · Atlanta, GANPI 1538346093

Payments from drug & device makers

$12,761in general payments, 2019–2025

Across 46 payments — averaging $277.41 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Dompe US, Inc.$3K
  • Carl Zeiss Meditec, Inc.$3K
  • Harrow Eye, LLC$2K
  • Novartis$2K
  • Shire North American Group Inc$700
  • AbbVie$694
  • plus $1K from 11 others

What the payments were for

  • Consulting fees$9,68976%
  • Speaking & faculty fees$1,25010%
  • Food & beverage$1,80514%
  • Gifts$170%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$12,761 in reported general payments places this provider in the 80th percentile of 481 ophthalmology providers in Georgia.

See all ophthalmology providers in Georgia

Medicare billing

Part B allowed, 2024
$157,897
Medicare patients
356
Services billed
1,320

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
RestasisCyclosporine47$67,002
XiidraLifitegrast15$24,602
Prednisolone Acetate298$12,593
Cyclosporine19$10,712
LumiganBimatoprost14$10,103
Restasis MultidoseCyclosporine12$6,675
Latanoprost340$5,129
Fluorometholone64$3,930
Travoprost21$3,754
Ketorolac Tromethamine115$2,462
Timolol Maleate64$2,012
Dorzolamide-TimololDorzolamide Hcl/Timolol Maleat101$1,599
ValacyclovirValacyclovir Hcl16$922
Dorzolamide Hcl26$504
MoxifloxacinMoxifloxacin Hcl13$330

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AbbVieRestasis, Lumigan, Restasis Multidose$694$83,78073 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 481 ophthalmology providers in Georgia.

Other ophthalmology in Atlanta

See the full list for Georgia

Where these figures come from

Is this you, or does something look wrong? →